Plasma midregional pro-atrial natriuretic peptide is associated with blood pressure indices and hypertension severity in adults with hypertension

American Journal of Hypertension

Volumn 22, Issue 4, 2009, Pages 425-431

  Khaleghi, Mahyar ^a   Saleem, Umer ^a   Morgenthaler, Nils G ^b   Turner, Stephen T ^a   Bergmann, Andreas ^b   Struck, Joachim ^b   Mosley, Thomas H ^c   Kullo, Iftikhar J ^a  

^a MAYO CLINIC   (United States)

^b THERMO FISHER SCIENTIFIC   (Germany)

^c UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE PRESSURE; SMOKING;

ADULT; AFRICAN AMERICANS; AGED; ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; MINNESOTA; MISSISSIPPI; VASCULAR RESISTANCE;

EID: 62849088757     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2009.8     Document Type: Article

References (33)

1. Sagnella GA, Markandu ND, Shore AC, MacGregor GA. Raised circulating levels of atrial natriuretic peptides in essential hypertension. Lancet 1986; 1:179-181.
2. Arendt RM, Gerbes AL, Ritter D, Stangl E, Bach P, Zahringer J. Atrial natriuretic factor in plasma of patients with arterial hypertension, heart failure or cirrhosis of the liver. J Hypertens Suppl 1986; 4: S131-S135.
3. Nilsson P, Lindholm L, Schersten B, Horn R, Melander A, Hesch RD. Atrial natriuretic peptide and blood pressure in a geographically defined population. Lancet 1987; 2: 883-885.
4. Zachariah PK, Burnett JC Jr, Ritter SG, Strong CG. Atrial natriuretic peptide in human essential hypertension. Mayo Clin Proc 1987; 62: 782-786.
5. Flickinger AL, Burnett JC Jr, Turner ST. Atrial natriuretic peptide and blood pressure in a population-based sample. Mayo Clin Proc 1995; 70: 932-938.
6. Wang TJ, Larson MG, Levy D, Leip EP, Benjamin EJ, Wilson PW, Sutherland P, Omland T, Vasan RS. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol 2002; 90: 254-258.
7. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, Leppaluoto J, Vuolteenaho O. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004; 50: 1576-1588.
8. Morgenthaler NG, Struck J, Thomas B, Bergmann A. Immunoluminometric assay for the midregion of pro-atrial natriuretic peptide in human plasma. Clin Chem 2004; 50: 234-236.
9. Gerszten RE, Accurso FJ, Bernard GR, Caprioli RM, Klee EW, Klee GG, Kullo IJ, Laguna TA, Roth FP, Sabatine M, Srinivas P, Wang TJ, Ware LB. Challenges in translating plasma proteomics from bench to bedside: update from the NHLBI clinical proteomics programs. Am J Physiol Lung Cell Mol Physiol 2008; 295: L16-L22.
10. Granger CB, Van Eyk JE, Mockrin SC, Anderson NL. National heart, lung, and blood institute clinical proteomics working group report. Circulation 2004; 109: 1697-1703.
11. Boerwinkle E. Multi-center genetic study of hypertension: the family blood pressure program (FBPP). Hypertension 2002; 39: 3-9.
12. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Am J Epidemiol 1989; 129: 687-702.
13. Medi-Span, Proprietary Concepts. Master Drug Data Base Documentation Manual Indianapolis, Indiana, Medi-Span, Inc, 1996, 2.1-2.8.
14. Ellington AA, Malik AR, Klee GG, Turner ST, Rule AD, Mosley TH Jr, Kullo IJ. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension 2007; 50: 708-714.
15. Knopman DS, Mosley TH Jr, Bailey KR, Jack CR Jr, Schwartz GL, Turner ST. Associations of microalbuminuria with brain atrophy and white matter hyperintensities in hypertensive sibships. J Neurol Sci 2008; 271: 53-60.
16. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986; 42: 121-130.
17. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. I: Natriuretic peptides. J Hypertens 1992; 10: 907-912.
18. Nakao K, Ogawa Y, Suga S, Imura H. Molecular biology and biochemistry of the natriuretic peptide system. II: Natriuretic peptide receptors. J Hypertens 1992; 10: 1111-1114.
19. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol 2007; 50: 2357-2368.
20. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000; 2: 198-205.
21. John SW, Krege JH, Oliver PM, Hagaman JR, Hodgin JB, Pang SC, Flynn TG, Smithies O. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995; 267: 679-681.
22. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension 1990; 16: 301-307.
23. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab 1996; 81: 3871-3876.
24. Charles CJ, Espiner EA, Richards AM. Cardiovascular actions of ANF: contributions of renal, neurohumoral, and hemodynamic factors in sheep. Am J Physiol 1993; 264: R533-538.
25. Khaleghi M, Al-Omari MA, Kondragunta V, Morgenthaler N, Struck J, Bergmann A, Mosley TH Jr, Kullo IJ. Relation of plasma midregional pro-atrial natriuretic peptide to target organ damage in adults with systemic hypertension. Am J Cardiol, in press.
26. Levy D, Hwang SJ, Kayalar A, Benjamin EJ, Vasan RS, Parise H, Larson MG, Wang TJ, Selhub J, Jacques PF, Vita JA, Keyes MJ, Mitchell GF. Associations of plasma natriuretic peptide, adrenomedullin, and homocysteine levels with alterations in arterial stiffness: the Framingham Heart Study. Circulation 2007; 115: 3079-3085.
27. Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003; 5: 599-606.
28. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Wilson PW, Vasan RS. Impact of obesity on plasma natriuretic peptide levels. Circulation 2004; 109: 594-600.
29. Khush KK, Gerber IL, McKeown B, Marcus G, Vessey J, Foster E, Chatterjee K, Michaels AD. Obese patients have lower B-type and atrial natriuretic peptide levels compared with nonobese. Congest Heart Fail 2006; 12: 85-90.
30. Codognotto M, Piccoli A, Zaninotto M, Mion M, Plebani M, Vertolli U, Tona F, Ruzza L, Barchita A, Boffa GM. Renal dysfunction is a confounder for plasma natriuretic peptides in detecting heart dysfunction in uremic and idiopathic dilated cardiomyopathies. Clin Chem 2007; 53: 2097-2104.
31. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Riegger GA, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 1998; 32: 1839-1844.
32. Flack JM, Ferdinand KC, Nasser SA. Epidemiology of hypertension and cardiovascular disease in African Americans. J Clin Hypertens (Greenwich) 2003; 5: 5-11.
33. Mitchell GF, Izzo JL Jr, Lacourciere Y, Ouellet JP, Neutel J, Qian C, Kerwin LJ, Block AJ, Pfeffer MA. Omapatrilat reduces pulse pressure and proximal aortic stiffness in patients with systolic hypertension: results of the conduit hemodynamics of omapatrilat international research study. Circulation 2002; 105: 2955-2961.